SUNITINIB IN THE TREATMENT OF PATIENTS WITH PROGRESSION OF GASTROINTESTINAL STROMAL TUMORS AFTER USE OF IMATINIB (GLEEVEC)
- Authors: Zhukova LG1, Vorontsova KA1, Zhukova L.G.1, Vorontsova K.A.1
-
Affiliations:
- Issue: No 17 (2010)
- Pages: 56-60
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278669
- ID: 278669
Cite item
Full Text
Abstract
The article is dedicated to the potentials of imatinib (Gleevec) and sunitinib (Sutent) use in treatment of gastrointestinal stromal tumors (GIST). Improvement in the treatment of GIST was associated with the emergence of Gleevec, but 10-15% of patients with GIST have primary resistance to imatinib; furthermore, against the background of use of imatinib progression of disease develops in 50% of cases within 2 years. In these situations, Sutent can be used in the treatment of patients with progression of GIST. The data for assessment of Sutent efficacy and safety as second-line treatment of common GIST in 11 patients are presented. As a first-line treatment, all patients had previously received imatinib. Against the background of Sutent use, successful tumor control was achieved in 9 of 11 patients. Two 2 clinical cases of Sutent use are presented; in one of cases, total duration of disease control was more than 5 years. Thus, at present patients with progression of GIST after application of Gleevec can use Sutent, which has high efficacy and minimal side effects.
About the authors
L G Zhukova
K A Vorontsova
Lyudmila Grigor'evna Zhukova
Karina Andreevna Vorontsova
References
- D'Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44-56.
- Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
- Blanke CD, Demetri GD, von Mehren Margaret. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol 2008;26:620-25.
- Blanke CD, Rankin C, Demetri GD. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. J Clin Oncol 2008;26:626-32.
- Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005;23:5795-04.
- Pfizer Inc. SUTENT, Summary of Product Characteristics. February 2009.
- Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
- Reichardt P, Kang Y, Ruka W, et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST [poster presentation]. J Clin Oncol 2008;26(15S):565s(Abstr 10548).
- George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis [poster presentation]. J Clin Oncol 2008;26(15S):566s (Abstr 10554).
Supplementary files
